NICE Gives Thumbs Up to AbbVie’s Humira

The UK’s drug pricing watchdog seems to have warmed to AbbVie’s Humira, recommending the drug be covered four months after one of its committees proposed rejecting it.

The National Institute for Health and Care Excellence recommends in a final appraisal determination that the National Health Service pay for the drug, provided that AbbVie drops the price.

Back in February, NICE’s appraisal committee expressed doubts about the drug’s cost-effectiveness as a treatment for moderate to severe hidradenitis suppurativa, noting that a cost-effectiveness formula for the drug hinged on “substantial uncertainties,” such as the lack of a meta-analysis from AbbVie.